GlassScriptPhysician profile
Jasmyn Buchanan
NPI 1124684097
$2,156.11
in general payments reported to CMS, 2019-2025
27 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $451 · 2023: $496 · 2024: $418 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $565.93 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $271.38 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $177.11 | 2022-2025 | Evenity, Otezla, Repatha |
| Boston Scientific Corporation | $174.93 | 2021-2025 | General - Pain Management |
| Intra-Sana Laboratories | $138.48 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Corcept Therapeutics | $119.24 | 2024-2025 | Korlym |
| Abbvie INC. | $93.86 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.29 | 2022-2025 | Jardiance |
| Pfizer INC. | $54.97 | 2024-2025 | |
| Astellas Pharma US INC | $51.97 | 2023-2025 | Veozah |
| Currax Pharmaceuticals LLC | $51.39 | 2021-2022 | |
| Glaxosmithkline, LLC. | $50.07 | 2022-2023 | Trelegy Ellipta |
| Nalu Medical, INC. | $37.47 | 2023-2025 | Nalu Neurostimulation System |
| Tactile Systems Technology INC | $36.63 | 2025 | Flexitouch Plus, Nimbl |
| Rhythm Pharmaceuticals, INC. | $25.90 | 2023 | Imcivree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.93 | 2024 | |
| Nevro Corp. | $24.72 | 2022 | |
| Viiv Healthcare Company | $22.33 | 2024 | Apretude |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.04 | 2023 | Xifaxan |
| Exact Sciences Corporation | $17.88 | 2025 | The Cologuard Plus Collection Kit |
| Nestle Healthcare Nutrition INC. | $15.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.57 | 2023 | |
| Impulse Dynamics (USA) INC. | $15.14 | 2023 | Optimizer |
| Biomerieux INC | $15.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.48 | 2025 | |
| Aimmune Therapeutics, INC. | $13.79 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.72 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmyn Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.